Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandra Trejo-Martin

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Chemical Research in Toxicology|July 29, 2024
Quantum-Mechanics Calculations Elucidate Skin-Sensitizing Pharmaceutical CompoundsJakub Kostal, Adelina Voutchkova-Kostal, Joel P Bercu, et al.
Regulatory Toxicology and Pharmacology : RTP|September 26, 2024
N-Nitrosamine drug substance related impurities (NDSRIs) - A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 DaJoel Bercu, Olivier Dirat, Krista Dobo, et al.
Regulatory Toxicology and Pharmacology : RTP|July 11, 2022
The utility of hERG channel inhibition data in the derivation of occupational exposure limitsJillian A Parker, Ernest S Fung, Alejandra Trejo-Martin, et al.
Chemical Research in Toxicology|May 9, 2022
An Evaluation of the Occupational Health Hazards of Peptide CouplersJessica C Graham, Alejandra Trejo-Martin, Martyn L Chilton, et al.
Regulatory Toxicology and Pharmacology : RTP|August 7, 2021
Calculating qualified non-mutagenic impurity levels: Harmonization of approachesJessica C Graham, Mark W Powley, Erika Udovic, et al.
Chemical Research in Toxicology|February 5, 2024
Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic PotencyDavid J Snodin, Alejandra Trejo-Martin, David J Ponting, et al.
Bioorganic & Medicinal Chemistry Letters|August 14, 2009
Spiropiperidine CCR5 antagonistsDavid M Rotstein, Stephen D Gabriel, Ferenc Makra, et al.
Regulatory Toxicology and Pharmacology : RTP|August 23, 2022
Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosaminesAlejandra Trejo-Martin, Joel P Bercu, Andrew Thresher, et al.
Environmental and Molecular Mutagenesis|July 24, 2019
In Vivo Mutagenicity Testing of Arylboronic Acids and EstersMelisa J Masuda-Herrera, Krista L Dobo, Michelle O Kenyon, et al.
Regulatory Toxicology and Pharmacology : RTP|May 31, 2023
Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs)Joel P Bercu, Melisa Masuda-Herrera, Alejandra Trejo-Martin, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Chemical Research in Toxicology|July 29, 2024
Quantum-Mechanics Calculations Elucidate Skin-Sensitizing Pharmaceutical CompoundsJakub Kostal, Adelina Voutchkova-Kostal, Joel P Bercu, et al.
Regulatory Toxicology and Pharmacology : RTP|September 26, 2024
N-Nitrosamine drug substance related impurities (NDSRIs) - A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 DaJoel Bercu, Olivier Dirat, Krista Dobo, et al.
Regulatory Toxicology and Pharmacology : RTP|July 11, 2022
The utility of hERG channel inhibition data in the derivation of occupational exposure limitsJillian A Parker, Ernest S Fung, Alejandra Trejo-Martin, et al.
Chemical Research in Toxicology|May 9, 2022
An Evaluation of the Occupational Health Hazards of Peptide CouplersJessica C Graham, Alejandra Trejo-Martin, Martyn L Chilton, et al.
Regulatory Toxicology and Pharmacology : RTP|August 7, 2021
Calculating qualified non-mutagenic impurity levels: Harmonization of approachesJessica C Graham, Mark W Powley, Erika Udovic, et al.
Chemical Research in Toxicology|February 5, 2024
Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic PotencyDavid J Snodin, Alejandra Trejo-Martin, David J Ponting, et al.
Bioorganic & Medicinal Chemistry Letters|August 14, 2009
Spiropiperidine CCR5 antagonistsDavid M Rotstein, Stephen D Gabriel, Ferenc Makra, et al.
Regulatory Toxicology and Pharmacology : RTP|August 23, 2022
Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosaminesAlejandra Trejo-Martin, Joel P Bercu, Andrew Thresher, et al.
Environmental and Molecular Mutagenesis|July 24, 2019
In Vivo Mutagenicity Testing of Arylboronic Acids and EstersMelisa J Masuda-Herrera, Krista L Dobo, Michelle O Kenyon, et al.
Regulatory Toxicology and Pharmacology : RTP|May 31, 2023
Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs)Joel P Bercu, Melisa Masuda-Herrera, Alejandra Trejo-Martin, et al.
Pageof 2